Biosimilars Podcast: What To Expect When Supreme Court Hears Amgen vs. Sandoz
Executive Summary
Pink Sheet's Brenda Sandburg talks to Prevision Policy’s Kate Rawson about who has the most at stake in the case, the questions she’ll be listening for during oral arguments, and what might be in store from the newest addition to the Supreme Court: Justice Neil Gorsuch.
You may also be interested in...
Ringside For Zarxio At Supreme Court: Biosimilar Stakeholders Line Up
High court set to determine timing of biosimilar marketing and how parties handle patent disputes in Sandoz v. Amgen. Stakeholders say the outcome will impact innovation, access to biosimilars and future litigation.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.